In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model
Tóm tắt
Multiple myeloma (MM) is a monoclonal malignancy characterized by abnormal proliferation of plasma cells. The disease clinically manifests as anemia, hypercalcemia, renal insufficiencies, and osteolytic damage. Osteolytic damage goes with severe bone pain, spinal instability, and pathological fracture, symptoms that are collectively referred to as multiple myeloma bone disease (MMBD). Polymethylmethacrylate (PMMA) bone cement is widely used for bone repair after MMBD surgery, owing to its excellent biomechanical properties and fast curing. To date, however, efficacy of drug-loading PMMA in inhibition of tumor growth and angiogenesis remains unknown. Here, we report that 17-AAG-loaded PMMA bone cement inhibits MM growth in vivo and suppresses tumor diffusion to peripheral tissues. In addition, 17-AAG-loaded PMMA promotes MM apoptosis by downregulating Bax and active Caspase-3.
Tài liệu tham khảo
Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:78–88.
Alegre A, Gironella M, Bailén A, Giraldo P. Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. Eur J Haematol. 2014;92:181–8.
Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA. Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Rev Hematol. 2018;11:881–8.
Ring ES, Lawson MA, Snowden JA, Jolley I, Chantry AD. New agents in the treatment of myeloma bone disease. Calcif Tissue Int. 2018;102:196–209.
Vallet S, Filzmoser JM, Pecherstorfer M, Podar K. Myeloma bone disease: update on pathogenesis and novel treatment strategies. Pharmaceutics. 2018;10:202.
Kelley SP, Ashford RU, Rao AS, Dickson RA. Primary bone tumours of the spine: a 42-year survey from the leeds regional bone tumour registry. Eur Spine. 2007;16:405–9.
Hussein MA, Vrionis FD, Allison R, et al. The role of vertebral augmentation in multiple myeloma: international myeloma working group consensus statement. Leukemia. 2008;22:1479–14.
Surgeon’s Committee of the Chinese Myeloma Working Group of the International Myeloma Foundation. Consensus on surgical management of myeloma bone disease. Orthopaedic Surg. 2016;8:263–9.
Zadnik PL, Goodwin CR, Karami KJ, et al. Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. J Neurosurg Spine. 2015;22:301–9.
Denaro V, Denaro L, Albo E, Papapietro N, Piccioli A, Martino Di. Surgical management of spinal fractures and neurological involvement in patients with myeloma. Injury. 2016;47(Suppl 4):S49-s53.
Igarashi K, Yamamoto N, Shirai T, et al. The long-term outcome following the use of frozen autograft treated with liquid nitrogen in the management of bone and soft-tissue sarcomas. Bone Joint J. 2014;96-b:555–61.
Kühn KD, Höntzsch D. Augmentation with PMMA cement. Unfallchirurg. 2015;118:737–48.
Shen J, Du X, Zhao L, Luo H, Xu Z. Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue. Oncol Lett. 2018;15:10017–25.
Yao X, Wei Y, Luo H, Du X. Anti-myeloma properties and mechanism of polymethyl methacrylate bone cement and allograft bone in vitro. Int J Clin Exp Med. 2019;12(1):1276–81.
Grosicki S, Bednarczyk M, Janikowska G. Heat shock proteins as a new, promising target of multiple myeloma therapy. Expert Rev Hematol. 2020;13:117–26.
Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14:e358-369.
Koto K, Murata H, Sawai Y, Ashihara E, Horii M, Kubo T. Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors. Oncol Lett. 2017;14:1648–56.
Wang J, Li Y, Sun W, Liu J, Chen W. Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells. Hematology. 2018;23:620–5.
Huang L, Okada K, Takahashi S, Suzuki N, Shimada Y, Itoi E. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI insight. 2020;5:e135544.
Tani T, Hatanaka K, Watanabe H, Asano Y, Yamagata H, Maruyama T. Doxorubicin-loaded calcium phosphate cement in the management of bone and soft tissue tumors. Vivo. 2006;20:55–60.
Matsui S, Doseff A, Chau BN, et al. A modification of Mayer’s tannic acid-ferric chloride staining method for demonstrating cellular membranous systems for light microscopy. Biotechnic Histochem. 2000;75:33–40.
Kirsch DG, Doseff A, Chau BN, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biolog Chem. 1999;274:21155–211.
Jakob C, et al. Angiogenesis in multiple myeloma. Eur J Cancer. 2006;42:1581–90.
Tsukahara S, et al. Inhalation of low-level formaldehyde increases the Bcl-2/Bax expression ratio in the hippocampus of immunologically sensitized mice. NeuroImmunoModulation. 2006;13:63–8.
Odonkor CA, Achilefu S. Modulation of effector caspase cleavage determines response of breast and lung tumor cell lines to chemotherapy. Cancer Invest. 2009;27:417–29. https://doi.org/10.1080/07357900802438585.
Calero R, Morchon E, Martinez-Argudo I, Serrano R. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett. 2017;406:1–11.
Tavernier E, et al. HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents. J Cancer Res Clin Oncol. 2012;138:1753–8.
Zhang X, Gao F, Zhong S. Combinatorial Inhibition of mTORC2 and Hsp90 leads to a distinctly effective therapeutic strategy in malignant Pheochromocytoma. Curr Cancer Drug Targets. 2019;19:698–706.
Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia. 2004;18:1891–7.